| 1 |
NCT00787722 |
Recruiting |
Hematopoietic Stem Cell Transplant in Devic's Disease |
|
- Procedure: Hematopoietic stem cell transplantation
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival
- Visual Acuity
- Decreased weakness in limb (MRS)
- (and 6 more...)
|
40 |
All |
16 Years to 65 Years (Child, Adult) |
NCT00787722 |
DIAD Devic's Disease Auto 2008 |
|
October 2008 |
October 2017 |
October 2018 |
November 7, 2008 |
July 21, 2017 |
|
- Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
|
| 2 |
NCT00904826 |
Completed
Has Results |
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica |
- Neuromyelitis Optica
- Devic's Disease
|
|
Interventional |
Phase 1
Phase 2 |
- Mayo Clinic
- Alexion Pharmaceuticals
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Median Number of Neuromyelitis Optica (NMO) Attacks Per Year
- Number Subjects Experiencing an NMO Attack in 12 Months of Eculizumab Treatment
- Change in Expanded Disability Status Scale (EDDS) Score
- (and 6 more...)
|
14 |
All |
18 Years and older (Adult, Senior) |
NCT00904826 |
09-001240 |
|
April 2009 |
December 2011 |
December 2011 |
May 20, 2009 |
November 4, 2013 |
November 4, 2013 |
- Mayo Clinic
Scottsdale, Arizona, United States - Mayo Clinic
Rochester, Minnesota, United States
|
| 3 |
NCT02865018 |
Completed |
Neuromyelitis Optica (NMO) & Cetirizine |
|
|
Interventional |
Phase 1
Phase 2 |
- Icahn School of Medicine at Mount Sinai
- Guthy Jackson Foundation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Annualized relapse rate before cetirizine
- Annualized relapse rate after cetirizine
- Epworth Sleepiness Scale
- (and 3 more...)
|
16 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02865018 |
13-1513 |
|
April 2014 |
February 2016 |
February 2016 |
August 12, 2016 |
August 12, 2016 |
|
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
|
| 4 |
NCT01759602 |
Completed
Has Results |
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation |
|
- Drug: C1-esterase inhibitor (Cinryze)
|
Interventional |
Phase 1 |
- Michael Levy
- ViroPharma
- Johns Hopkins University
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Adverse Safety Events During Hospitalization
- Frequency of Serious Adverse Events.
- Percentage of Subjects Withdrawing Due to Adverse Events.
- (and 2 more...)
|
10 |
All |
18 Years to 65 Years (Adult) |
NCT01759602 |
NA_00078437 |
|
January 2013 |
November 2013 |
November 2013 |
January 3, 2013 |
July 18, 2014 |
July 18, 2014 |
- Johns Hopkins Hospital
Baltimore, Maryland, United States
|
| 5 |
NCT02087813 |
Unknown † |
Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses |
|
- Drug: Alpha1-antitrypsin
- Drug: methylprednisolone
|
Interventional |
Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean change in disability from baseline/nadir to week 24 as assessed by Opticospinal Impairment Score (OSIS) subscale.
- Mean change in disability from baseline/nadir to week 24 as assessed by Expanded Disability Status Scale (EDSS).
- For patients experiencing optic neuritis, mean change in visual acuity from baseline/nadir to week 24 as assessed by Sloan 2.5% low contrast visual acuity chart.
- (and 2 more...)
|
5 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02087813 |
IRB-27176 |
A1AT for NMO |
March 2014 |
March 2016 |
|
March 14, 2014 |
March 14, 2014 |
|
- Stanford University
Stanford, California, United States
|
| 6 |
NCT01339455 |
Terminated |
Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica |
|
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion relapse-free at three years
- Proportion relapse-free at five years
- Relapse count
- (and 7 more...)
|
3 |
All |
18 Years to 65 Years (Adult) |
NCT01339455 |
CHREB ID# 23282 |
SCT-NMO |
March 2011 |
March 2020 |
December 2020 |
April 20, 2011 |
October 25, 2017 |
|
- Foothills Medical Centre, University of Calgary
Calgary, Alberta, Canada
|
| 7 |
NCT02021825 |
Unknown † |
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders |
- Neuromyelitis Optica
- Neuromyelitis Optica Spectrum Disorders
|
|
Interventional |
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- annual relapse rate (ARR)
- EDSS
- Changes in LVEF
- (and 2 more...)
|
50 |
All |
18 Years to 55 Years (Adult) |
NCT02021825 |
MITONMO |
|
March 2009 |
December 2014 |
December 2015 |
December 27, 2013 |
December 27, 2013 |
|
- Department of Neurology, Xuanwu Hospital, Capital Medical University
Beijing, Beijing, China
|
| 8 |
NCT02276963 |
Active, not recruiting |
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses |
- Neuromyelitis Optica
- Neuromyelitis Optica Spectrum Disorder
|
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events
- MRI spine
- Neurological Disability - Expanded Disability Scale Score
- (and 2 more...)
|
5 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02276963 |
IRB00052958 |
|
September 2015 |
July 2017 |
July 28, 2018 |
October 28, 2014 |
March 16, 2018 |
|
- Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
|
| 9 |
NCT01845584 |
Completed |
Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. |
- Neuromyelitis Optica Spectrum Disorder
|
|
Interventional |
Phase 2 |
- Nihon Pharmaceutical Co., Ltd
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from Baseline Quantification of nerve and spinal cord impairment （QOSI） at 29 days
- Change from Baseline Expanded Disability Status Scale （EDSS）/ Functional Systems （FS） at 29 days
- Change from Baseline anti-aquaporin 4 antibody at 29 days
|
7 |
All |
20 Years and older (Adult, Senior) |
NCT01845584 |
NPB-01-08/E-01 |
|
May 2013 |
August 2015 |
August 2015 |
May 3, 2013 |
April 12, 2017 |
|
|
| 10 |
NCT00501748 |
Completed |
Safety and Tolerability of Rituximab in Neuromyelitis Optica |
|
|
Interventional |
Phase 1 |
- University of California, San Francisco
- Genentech, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and Tolerability of Rituximab in NMO (monitor for any AE during two years of follow up)
- Time from treatment to recurrence of either optic neuritis or myelitis
- Change in Kurtzke expanded disability status scale (EDSS) at weeks 4, 12, 24, 48, 72, 96
|
20 |
All |
12 Years to 86 Years (Child, Adult, Senior) |
NCT00501748 |
H7620-25392-04 |
|
January 2004 |
December 2010 |
December 2010 |
July 16, 2007 |
September 27, 2011 |
|
- UCSF MS Center , 350 Parnassus Ave , suite #908
San Francisco, California, United States - The Neurological Institute of New York MS Center
Columbia University Medical Center 710 West 168th Street,, New York, United States
|
| 11 |
NCT02893111 |
Active, not recruiting |
Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder |
- Neuromyelitis Optica Spectrum Disorder
|
|
Interventional |
Phase 2 |
- Tianjin Medical University General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Annual relapse rate (ARR) of NMOSD Attacks
- Number of Participants with Adverse Events
- Change in Expanded Disability Status Scale (EDDS) Score
- (and 6 more...)
|
5 |
Female |
18 Years and older (Adult, Senior) |
NCT02893111 |
IRB2016-YX-021 |
|
December 2015 |
October 2017 |
December 2017 |
September 8, 2016 |
September 8, 2016 |
|
- Tianjin Medical University General Hospital
Tianjin, Tianjin, China
|
| 12 |
NCT02200770 |
Recruiting |
A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders |
- Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
|
- Biological: MEDI-551
- Other: Placebo
|
Interventional |
Phase 2
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to onset of an adjudicated NMO/NMOSD attack
- Attack Rate
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- (and 6 more...)
|
252 |
All |
18 Years and older (Adult, Senior) |
NCT02200770 |
CD-IA-MEDI-551-1155
2014-000253-36 |
|
January 6, 2015 |
November 6, 2019 |
November 1, 2023 |
July 25, 2014 |
April 6, 2018 |
|
- Research Site
Birmingham, Alabama, United States - Research Site
Irvine, California, United States - Research Site
Sacramento, California, United States - (and 144 more...)
|
| 13 |
NCT03350633 |
Recruiting |
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders |
- Neuromyelitis Optica Spectrum Disorders
- Neuromyelitis Optica
|
- Drug: Tocilizumab Injection
- Drug: Azathioprine
|
Interventional |
Phase 2
Phase 3 |
- Tianjin Medical University General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to first relapse
- Proportion of patients who experience relapse-free
- Worsening in EDSS
- (and 15 more...)
|
118 |
All |
18 Years and older (Adult, Senior) |
NCT03350633 |
IRB2017-YX-009 |
TANGO |
October 15, 2017 |
December 2018 |
June 2019 |
November 22, 2017 |
November 22, 2017 |
|
- Tianjin Medical University General Hospital
Tianjin, Tianjin, China
|
| 14 |
NCT03330418 |
Recruiting |
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders |
- Neuromyelitis Optica Spectrum Disorders
|
- Biological: Placebo
- Biological: RC18 160 mg
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to first relapse after randomization
- Change from Baseline in Expanded Disability Status Scale (EDSS) Score at week 4,8,12,24,36,48,60,72,96,120,144
- Change from Baseline in Hauser Ambulation Index at week 4,8,12,24,36,48,60,72,96,120,144
|
118 |
All |
18 Years to 65 Years (Adult) |
NCT03330418 |
C009NMOSDCLLI |
|
September 21, 2017 |
December 2020 |
June 2021 |
November 6, 2017 |
November 7, 2017 |
|
- Beijing Hospital
Beijing, Beijing, China
|
| 15 |
NCT02850705 |
Recruiting |
The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) |
- Neuromyelitis Optica Spectrum Disorders
- Neuromyelitis Optica Spectrum Related Disorders
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- number of cases of NMO or NMOSD included in the cohort
|
650 |
All |
Child, Adult, Senior |
NCT02850705 |
D50742 |
NOMADMUS |
January 2010 |
January 2019 |
January 2019 |
August 1, 2016 |
January 12, 2018 |
|
- Hospices Civils de Lyon / Hopital Neurologique Pierre Wertheimer
Bron, France
|
| 16 |
NCT01364246 |
Unknown † |
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica |
- Progressive Multiple Sclerosis
- Neuromyelitis Optica.
|
- Biological: human umbilical cord mesenchymal stem cells
|
Interventional |
Phase 1
Phase 2 |
- Shenzhen Beike Bio-Technology Co., Ltd.
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- The Affiliated Nanjing Brain Hospital of Nanjing University Medical School
- (and 3 more...)
|
Industry / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Score of Expanded Disability Status Scale (EDSS)
- Visual Evoked Potential (VEP)
- Brainstem Auditory Evoked Potential (BAEP)
- (and 2 more...)
|
20 |
All |
18 Years to 60 Years (Adult) |
NCT01364246 |
BKCR-MS-1.0(2010) |
|
January 2010 |
March 2013 |
December 2014 |
June 2, 2011 |
November 28, 2012 |
|
- Nanjing University Medical College Affiliated Drum Tower Hospital
Nanjing, Jiangsu, China
|
| 17 |
NCT02003144 |
Enrolling by invitation |
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients |
- Neuromyelitis Optica
- Neuromyelitis Optica Spectrum Disorder
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate the long-term safety of eculizumab in patients with relapsing NMO.
- Evaluate the long-term efficacy of eculizumab in patients with relapsing NMO
|
132 |
All |
18 Years and older (Adult, Senior) |
NCT02003144 |
ECU-NMO-302
2013-001151-12 |
|
January 2015 |
December 2018 |
December 2018 |
December 6, 2013 |
March 8, 2018 |
|
- Mayo Clinic Arizona
Scottsdale, Arizona, United States - The Research Center of Southern California
Oceanside, California, United States - Christiana Care Neurology Spec,
Newark, Delaware, United States - (and 85 more...)
|
| 18 |
NCT01892345 |
Active, not recruiting |
A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) |
- Neuromyelitis Optica
- Neuromyelitis Optica Spectrum Disorder
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to first relapse
- Overall safety and tolerability of eculizumab
|
132 |
All |
18 Years and older (Adult, Senior) |
NCT01892345 |
ECU-NMO-301 |
|
January 2014 |
May 2018 |
May 2018 |
July 4, 2013 |
March 7, 2018 |
|
- Mayo Clinic Arizona
Scottsdale, Arizona, United States - The Research Center of Southern California
Oceanside, California, United States - Christiana Care Neurology Spec,
Newark, Delaware, United States - (and 90 more...)
|
| 19 |
NCT03452176 |
Recruiting |
Scrambler Trial for Pain in NMOSD |
|
- Device: Scrambler
- Device: Scrambler Sham Control
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Acceptability
- Feasibility
- Change in Pain Level
|
22 |
All |
18 Years and older (Adult, Senior) |
NCT03452176 |
IRB00115699 |
|
February 21, 2018 |
June 30, 2019 |
September 30, 2019 |
March 2, 2018 |
April 6, 2018 |
|
- Johns Hopkins University
Baltimore, Maryland, United States
|
| 20 |
NCT02249676 |
Unknown † |
Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders |
- Devic's Syndrome
- Devic's Neuromyelitis Optica
- Devic Syndrome
- (and 2 more...)
|
- Biological: Autologous mesenchymal stem cells
|
Interventional |
Phase 2 |
- Tianjin Medical University General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- EDSS
- Annual relapse rate
- Lesion load
- (and 4 more...)
|
15 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02249676 |
IRB2013-055-02 |
|
January 2013 |
December 2014 |
December 2014 |
September 25, 2014 |
September 25, 2014 |
|
- Tianjin Medical University General Hospital
Tianjin, Tianjin, China
|
| 21 |
NCT03062579 |
Active, not recruiting |
A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD |
- Neuromyelitis Optica Spectrum Disorders
- Neuromyelitis Optica
- Devic's Disease
|
|
Interventional |
Phase 1
Phase 2 |
- Fu-Dong Shi
- Tianjin Medical University General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Median Number of Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks Per Year
- Number of Participants with Adverse Events
- Neurological Disability - Expanded Disability Scale Score (EDSS)
- (and 8 more...)
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT03062579 |
IRB2017-YX-006 |
|
December 1, 2016 |
January 1, 2018 |
April 1, 2018 |
February 23, 2017 |
February 23, 2017 |
|
- Tianjin Medical University General Hospital
Tianjin, Tianjin, China
|
| 22 |
NCT03002038 |
Completed |
Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients |
- Neuromyelitis Optica Spectrum Disorder
|
- Drug: Azathioprine
- Drug: Rituximab
|
Interventional |
Phase 2
Phase 3 |
- Isfahan University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Annual Relapse Rate
- Expanded Disability Status Scale
|
76 |
All |
18 Years to 50 Years (Adult) |
NCT03002038 |
395275 |
|
September 2015 |
November 2016 |
December 2016 |
December 23, 2016 |
January 2, 2017 |
|
- Kashani Hospital
Isfahan, Iran, Islamic Republic of
|
| 23 |
NCT02836327 |
Recruiting |
Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders |
- Multiple Sclerosis
- Neuromyelitis Optica Spectrum Disorders
|
- Other: Magnetic Resonance Imaging
|
Observational |
|
- Chinese PLA General Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
300 |
All |
18 Years to 60 Years (Adult) |
NCT02836327 |
MS and NMOSD-ChinaPLAGH |
|
September 2014 |
September 2019 |
September 2021 |
July 19, 2016 |
August 9, 2016 |
|
- Chinese PLA General Hospital
Beijing, Beijing, China
|
| 24 |
NCT01777412 |
Completed
Has Results |
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations |
- Neuromyelitis Optica
- Neuromyelitis Optica Spectrum Disorder
|
|
Interventional |
Phase 1 |
- Johns Hopkins University
- Genentech, Inc.
- Guthy Jackson Charitable Foundation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Baseline Expanded Disability Status Score (EDSS)
- Safety Assessment and Side Effects
- Follow-Up Expanded Disability Status Score (EDSS)
|
10 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01777412 |
Avastin_NMO_1 |
|
June 2013 |
February 2015 |
May 2015 |
January 28, 2013 |
August 21, 2015 |
May 29, 2015 |
- Johns Hopkins Hospital
Baltimore, Maryland, United States
|
| 25 |
NCT01500681 |
Active, not recruiting |
Maintenance Plasma Exchange for Neuromyelitis Optica |
- Neuromyelitis Optica
- Neuromyelitis Optica Spectrum Disorder
- Recurrent Idiopathic Longitudinally Extensive Transverse Myelitis
|
- Procedure: Plasma exchange (PLEX)
|
Observational |
|
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of participants who complete planned maintenance PLEX regimen
- Number of participants with adverse events
- Annualized clinical relapse rate
- Median Expanded Disability Status Score (EDSS)
|
14 |
All |
18 Years and older (Adult, Senior) |
NCT01500681 |
10-007339
MultiPLEX-2012 |
MultiPLEX |
June 2012 |
August 2017 |
|
December 28, 2011 |
March 22, 2017 |
|
- Mayo Clinic
Scottsdale, Arizona, United States - Mayo Clinic
Rochester, Minnesota, United States
|
| 26 |
NCT01024985 |
Unknown † |
Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct |
- Multiple Sclerosis
- Neuromyelitis Optica
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
40 |
All |
15 Years to 60 Years (Child, Adult) |
NCT01024985 |
0190/09 |
|
September 2009 |
December 2010 |
December 2011 |
December 3, 2009 |
June 28, 2010 |
|
- Hospital Das Clinicas Medical School of University of Sao Paulo
Sao Paulo, Brazil
|
| 27 |
NCT02028884 |
Recruiting |
Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD |
- Neuromyelitis Optica (NMO)
- NMO Spectrum Disorder (NMOSD)
|
- Drug: satralizumab (SA237)
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time to first relapse
- Annualized relapse rate
|
70 |
All |
12 Years to 74 Years (Child, Adult, Senior) |
NCT02028884 |
SA-307JG
2013-003752-21 |
|
February 2014 |
July 2018 |
June 2020 |
January 7, 2014 |
March 12, 2018 |
|
- Birmingham, Alabama, United States
- Children's Specialty Center Of Nevada
Las Vegas, Nevada, United States - Philadelphia, Pennsylvania, United States
- (and 53 more...)
|
| 28 |
NCT02809079 |
Enrolling by invitation |
Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients |
- Neuromyelitis Optica Spectrum Disorders
- Mycophenolate Mofetil
- Efficacy and Safety
|
- Drug: Mycophenolate mofetil
- Drug: Prednisone
|
Interventional |
Phase 4 |
- Third Affiliated Hospital, Sun Yat-Sen University
- Zhongshan Ophthalmic Center, Sun Yat-sen University
- Nangfang Hospital, Southern Medical University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Annualized relapse rate day 360
- expanded disability status scale
- Hauser scale
- (and 3 more...)
|
100 |
All |
18 Years to 65 Years (Adult) |
NCT02809079 |
2016017 |
MONICA |
January 2016 |
December 2017 |
December 2017 |
June 22, 2016 |
June 22, 2016 |
|
|
| 29 |
NCT02073279 |
Active, not recruiting |
Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD |
- Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
|
- Drug: satralizumab (SA237)
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time to first relapse
- Annualized relapse rate
|
95 |
All |
18 Years to 74 Years (Adult, Senior) |
NCT02073279 |
SA-309JG |
|
August 2014 |
October 2018 |
March 2019 |
February 27, 2014 |
October 31, 2017 |
|
- University of California, Irvine
Irvine, California, United States - UC Davis Medical System
Sacramento, California, United States - University of Colorado
Aurora, Colorado, United States - (and 74 more...)
|
| 30 |
NCT00304291 |
Completed |
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) |
- Neuromyelitis Optica
- Myelitis, Transverse
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
|
|
Interventional |
Phase 4 |
- State University of New York at Buffalo
- EMD Serono
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
5 |
All |
18 Years to 55 Years (Adult) |
NCT00304291 |
JNI-NMO-101 |
|
August 2001 |
|
May 2004 |
March 17, 2006 |
November 28, 2006 |
|
- Baird Multiple Sclerosis Center
Buffalo, New York, United States
|
| 31 |
NCT02283671 |
Recruiting |
Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B |
- Multiple Sclerosis
- Neuromyelitis Optica
|
- Biological: Tolerogenic Dendritic cells loaded with myelin peptides
|
Interventional |
Phase 1 |
- Sara Varea
- Fundacion Clinic per a la Recerca Biomédica
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- number of patients with adverse events
- Multiple Sclerosis Functional Composite scale
- Multiple Sclerosis Spasticity Scale
- (and 5 more...)
|
22 |
All |
18 Years to 65 Years (Adult) |
NCT02283671 |
TolDec-EM-NMO |
|
September 2015 |
December 2018 |
December 2018 |
November 5, 2014 |
November 7, 2017 |
|
- Hospital Clinic of Barcelona
Barcelona, Spain
|
| 32 |
NCT02398994 |
Terminated |
A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis |
- Myelitis, Transverse
- Neuromyelitis Optica
|
- Drug: Intravenous Methylprednisolone
- Drug: Intravenous Immunoglobulin
|
Interventional |
Phase 3 |
- Guy's and St Thomas' NHS Foundation Trust
- King's College London
- Barts and the London School of Medicine and Dentistry
- (and 19 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- 2 points or greater improvement on the American Spinal Injury Association (ASIA) Impairment scale (classified A-E)
- Change in ASIA motor scale (0-100) and ASIA sensory scale (0-112)
- Change in Kurtzke's expanded disability status scale (EDSS) measured with Neurostatus scoring
- (and 4 more...)
|
2 |
All |
1 Year and older (Child, Adult, Senior) |
NCT02398994 |
RJ115/N065
2014-002335-34
11/129/148
12127581 |
STRIVE |
March 2015 |
March 2016 |
March 2016 |
March 26, 2015 |
July 20, 2016 |
|
- Birmingham Children's Hospital NHS Foundation Trust
Birmingham, United Kingdom - University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom - North Bristol NHS Trust
Bristol, United Kingdom - (and 15 more...)
|
| 33 |
NCT02889965 |
Recruiting |
The French Multiple Sclerosis Registry |
- Multiple Sclerosis
- Neuromyelitis Optica Spectrum Disorders
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of cases of MS included
- number of patients
- demographic characteristics
- (and 3 more...)
|
54000 |
All |
up to 100 Years (Child, Adult, Senior) |
NCT02889965 |
69HCL14_0385 |
OFSEP |
January 2011 |
December 2019 |
December 2019 |
September 7, 2016 |
September 7, 2016 |
|
- Hospices Civils de Lyon / Hopital Neurologique Pierre Wertheimer
Bron, France
|
| 34 |
NCT03370965 |
Not yet recruiting |
Optic Neuritis Differential Diagnosis Study |
- Optic Neuritis
- Neuromyelitis Optica
- Multiple Sclerosis
|
- Diagnostic Test: Neuro-ophtalmology examination
|
Interventional |
Not Applicable |
- University Hospital Center of Martinique
- University Hospital Center of Guadeloupe
- Hospital Center of Cayenne (French Guyana)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Final diagnosis using MS (McDonald, 2010) - Spatial dissemination
- Final diagnosis using MS (McDonald, 2010) - Time dissemination
- NMO diagnosis criteria (Wingerchuk, 2015) - Diagnosis of NMO-SD with positive anti-AQP4 Antibody
- NMO diagnosis criteria (Wingerchuk, 2015) - Diagnosis of NMO-SD with anti-AQP4 negative antibody
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT03370965 |
17/B/01 |
ONDDS |
January 2018 |
January 2023 |
October 2023 |
December 13, 2017 |
December 13, 2017 |
|
|
| 35 |
NCT01623076 |
Recruiting |
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders |
- Neuromyelitis Optica
- Neuromyelitis Optica Spectrum Disorder
- Transverse Myelitis
- Optic Neuritis
|
|
Observational |
|
- University of Texas Southwestern Medical Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Measure change in standard clinical assessments over time
- Measure change in cognition measures over time
- Measure change in self-reported quality of life surveys
- B cell population changes
|
150 |
All |
6 Years and older (Child, Adult, Senior) |
NCT01623076 |
STU-022012-084 |
|
June 2012 |
June 2020 |
June 2022 |
June 19, 2012 |
January 3, 2018 |
|
- The University of Texas Southwestern Medical Center
Dallas, Texas, United States
|
| 36 |
NCT02166346 |
Completed
Has Results |
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) |
- Transverse Myelitis
- Neuromyelitis Optica
- Idiopathic Transverse Myelitis
- Myelitis NOS
|
- Drug: Dalfampridine
- Drug: Placebo
|
Interventional |
Phase 2 |
- Johns Hopkins University
- Acorda Therapeutics
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Walking Speed During Timed 25-foot Walk
- Upper and Lower Extremity Muscle Strength Measurements
|
24 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02166346 |
NA_00090799 |
|
February 2014 |
January 8, 2017 |
January 8, 2017 |
June 18, 2014 |
April 17, 2018 |
April 17, 2018 |
- Johns Hopkins University
Baltimore, Maryland, United States
|
| 37 |
NCT03138421 |
Recruiting |
Central Pain Study for ABX-1431 |
- Neuromyelitis Optica Spectrum Disorder
- Transverse Myelitis
- Multiple Sclerosis
- Longitudinally Extensive Transverse Myelitis
|
- Drug: ABX-1431 HCl
- Drug: Placebo
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in mean pain score between ABX-1431 HCl and placebo based on the Pain NRS-11 ordinal numeric rating scale
- Short Form Brief Pain Inventory (SF-BPI) Scores
- Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2)
- (and 6 more...)
|
32 |
All |
18 Years and older (Adult, Senior) |
NCT03138421 |
ABX-1431_PN009 |
|
August 1, 2017 |
February 2018 |
February 2018 |
May 3, 2017 |
August 4, 2017 |
|
- The Walton Centre
Liverpool, United Kingdom - Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
|
| 38 |
NCT00445367 |
Active, not recruiting |
Biobank For MS And Other Demyelinating Diseases |
- Multiple Sclerosis
- Transverse Myelitis
- Neuromyelitis Optica
- (and 2 more...)
|
|
Observational |
|
- Accelerated Cure Project for Multiple Sclerosis
|
Other |
- Observational Model: Case-Control
- Time Perspective: Other
|
|
3226 |
All |
Child, Adult, Senior |
NCT00445367 |
ACP-001 |
|
May 2006 |
October 2026 |
|
March 9, 2007 |
January 17, 2018 |
|
- Barrow Neurological Institute
Phoenix, Arizona, United States - Stanford University
Stanford, California, United States - The Rocky Mountain MS Center at Anschutz Medical Campus at UC Denver
Aurora, Colorado, United States - (and 7 more...)
|
| 39 |
NCT00004645 |
Unknown † |
Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone |
- Acute Disseminated Encephalomyelitis
- Devic's Syndrome
- Marburg's Variant of Multiple Sclerosis
- (and 2 more...)
|
- Procedure: Plasma exchange
|
Interventional |
Phase 3 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- Mayo Clinic
- Office of Rare Diseases (ORD)
|
NIH / Other |
- Allocation: Randomized
- Masking: Double
- Primary Purpose: Treatment
|
|
22 |
All |
18 Years to 60 Years (Adult) |
NCT00004645 |
199/11693
MAYOC-29493 |
|
January 1995 |
|
|
February 25, 2000 |
June 24, 2005 |
|
|
| 40 |
NCT03121105 |
Active, not recruiting |
Pathologic-MRI Findings in Atypical IIDD |
- Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System
|
|
Observational |
|
- University Hospital, Montpellier
- Strasbourg University Hospital
- Rennes University Hospital
- (and 6 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- pathological
- MRI (magnetic resonnance Imaging)
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT03121105 |
RECHMPL17_0078 |
IIDD |
January 1, 2017 |
December 1, 2017 |
December 31, 2017 |
April 19, 2017 |
November 27, 2017 |
|
|
| 41 |
NCT03011541 |
Recruiting |
Stem Cell Ophthalmology Treatment Study II |
- Retinal Disease
- Age-Related Macular Degeneration
- Retinitis Pigmentosa
- (and 15 more...)
|
- Procedure: Arm 1
- Procedure: Arm 2
- Procedure: Arm 3
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Visual Acuity
- Visual Fields
- Optical Coherence Tomography (OCT)
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT03011541 |
SCOTS2 |
SCOTS2 |
January 2016 |
January 2020 |
January 2021 |
January 5, 2017 |
February 5, 2018 |
|
- The Healing Institute
Margate, Florida, United States
|
| 42 |
NCT01920867 |
Enrolling by invitation |
Stem Cell Ophthalmology Treatment Study |
- Retinal Disease
- Macular Degeneration
- Hereditary Retinal Dystrophy
- (and 2 more...)
|
- Procedure: RB (Retrobulbar)
- Procedure: ST (Subtenon)
- Procedure: IV (Intravenous)
- (and 2 more...)
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Visual acuity
- Visual fields
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT01920867 |
ICMS-2013-0019. |
SCOTS |
August 2013 |
August 2018 |
August 2019 |
August 12, 2013 |
January 18, 2018 |
|
- The Healing Institute
Margate, Florida, United States - Al Zahra Hospital
Dubai, United Arab Emirates
|
Create an RSS feed from your search for:
Download the search results for: